Cargando…
Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of plasmid CXCL9 synergizes with plasmid IL-12 therapy to elicit robust anti-tumor immunity
Clinical studies have demonstrated that local expression of the cytokine IL-12 drives interferon-gamma expression and recruits T cells to the tumor microenvironment, ultimately yielding durable systemic T cell responses. Interrogation of longitudinal biomarker data from our late-stage melanoma trial...
Autores principales: | Lee, Jack Y., Nguyen, Bianca, Mukhopadhyay, Anandaroop, Han, Mia, Zhang, Jun, Gujar, Ravindra, Salazar, Jon, Hermiz, Reneta, Svenson, Lauren, Browning, Erica, Lyerly, H. Kim, Canton, David A., Fisher, Daniel, Daud, Adil, Algazi, Alain, Skitzki, Joseph, Twitty, Christopher G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9092072/ https://www.ncbi.nlm.nih.gov/pubmed/35592387 http://dx.doi.org/10.1016/j.omto.2022.04.005 |
Ejemplares similares
-
Intratumoral electroporation of plasmid interleukin-12: efficacy and biomarker analyses from a phase 2 study in melanoma (OMS-I100)
por: Daud, Adil, et al.
Publicado: (2015) -
Epithelial chemokine CXCL14 synergizes with CXCL12 via allosteric modulation of CXCR4
por: Collins, Paul J., et al.
Publicado: (2017) -
Effective Treatments for Bladder Cancer Affecting CXCL9/CXCL10/CXCL11/CXCR3 Axis: A Review
por: Nazari, Alireza, et al.
Publicado: (2020) -
Overproduction of CXC chemokines CXCL1, CXCL9, CXCL10 and CXCL12 in β-thalassemia major or patients
por: Najmaddini, Hamid, et al.
Publicado: (2014) -
CXCL8, CXCL9, CXCL10, and CXCL11 as biomarkers of liver injury caused by chronic hepatitis B
por: Yu, Xin, et al.
Publicado: (2022)